Chickenpox vaccine - Merck & Co

Drug Profile

Chickenpox vaccine - Merck & Co

Alternative Names: Provarivax; V211; Varicella zoster virus vaccine live - Merck & Co; Variped; Varivax; Varivax II; Varivax ISF; Zostavax

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Osaka University
  • Developer CSL; Merck & Co; sanofi pasteur MSD
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster; Varicella zoster virus infections

Most Recent Events

  • 17 Oct 2017 Merck initiates enrolment in the V210-A03 phase III trial for Varicella zoster virus infections (Prevention) in USA (NCT03239873)
  • 08 Aug 2017 Merck Sharp & Dohme plans a phase III trial for Varicella zoster virus infections (Prevention, In In infants) (NCT03239873)
  • 28 Feb 2017 Merck has patent protection for Zostavax® in Europe (Merck Annual report 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top